Modulating <i>Bacteroides</i> to boost anti-PD-1 immunotherapy in HCC
<i>B.th</i> is identified as a key immunomodulatory species that enhances anti-PD-1 efficacy by reprogramming DCs through the KLF2/TLR9 signaling pathway. These findings reveal a novel microbiota-informed strategy to improve immunotherapeutic outcomes in HCC.
Authors
- Eric T. Kimchi (ORCID: https://orcid.org/0000-0002-5046-1142)
- Xinjian Liu (ORCID: https://orcid.org/0000-0002-1109-1740)
- Aaron C. Ericsson (ORCID: https://orcid.org/0000-0002-3053-7269)
- F. Staveley-O’Carroll Kevin
- Lixin Ma
- Ming Yang
- Jussuf T Kaifi
- Xiaoqiang Qi
Institutions
- Harry S. Truman Memorial Veterans' Hospital (US)
- UConn Health (US)
- University of Missouri (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1136/jitc-2025-013755
- Primary Topic
- Gut microbiota and health
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Zhejiang University